MCID: CLL001
MIFTS: 42

Cellular Schwannoma

Categories: Cancer diseases

Aliases & Classifications for Cellular Schwannoma

MalaCards integrated aliases for Cellular Schwannoma:

Name: Cellular Schwannoma 12 14 69
Cellular Neurinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3196
NCIt 47 C4724
UMLS 69 C0431124

Summaries for Cellular Schwannoma

Disease Ontology : 12 A neurilemmoma with a predominantly cellular growth but no Verocay bodies.

MalaCards based summary : Cellular Schwannoma, also known as cellular neurinoma, is related to neurofibromatosis-noonan syndrome and mitochondrial metabolism disease. An important gene associated with Cellular Schwannoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Pathways in cancer and Neuroscience. The drugs Anti-Bacterial Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and bone, and related phenotypes are Increased proliferation and cellular

Related Diseases for Cellular Schwannoma

Diseases related to Cellular Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Related Disease Score Top Affiliating Genes
1 neurofibromatosis-noonan syndrome 10.9 NF1 NF2
2 mitochondrial metabolism disease 10.7 S100A1 S100B
3 bone epithelioid hemangioma 10.7 S100A1 SLC2A1
4 spleen cancer 10.7 NF1 S100B
5 enteric pattern testicular yolk sac tumor 10.6 NF1 S100B
6 noninvasive malignant thymoma 10.6 NF2 S100B
7 pediatric fibrosarcoma 10.6 NF1 NF2
8 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.6 CDKN2A NF2
9 brain stem astrocytic neoplasm 10.6 NF1 TP53
10 fallopian tube serous papilloma 10.6 NF1 NGFR SOX10
11 verruciform xanthoma of skin 10.6 CD34 NF2
12 renal pelvis urothelial papilloma 10.6 NF2 TP53
13 cellular neurofibroma 10.6 CD34 DSP
14 cervical adenosquamous carcinoma 10.5 CDKN2A NF2
15 tropical spastic paraparesis 10.5 CD34 NF2
16 lice infestation 10.5 S100B SOX10
17 transitional meningioma 10.5 CD34 NF2
18 intraductal breast myoepitheliosis 10.5 NF2 TP53
19 malt worker's lung 10.4 SLC2A1 TP53
20 thai symphalangism syndrome 10.4 NGFR TP53
21 third cranial nerve disease 10.4 NF2 TP53
22 hemangioma of liver 10.4 S100B TP53
23 amelogenesis imperfecta local hypoplastic 10.4 CDKN2A SLC2A1
24 prostate disease 10.4 DSP S100B SLC2A1
25 cervical adenoid cystic carcinoma 10.4 CDKN2A TP53
26 diencephalic astrocytomas 10.3 CDKN2A NF1 SOX10
27 lymphoplasmacytic lymphoma 10.3 NF1 NF2 TP53
28 pleuropneumonia 10.3 CD34 CDKN2A
29 split hand split foot nystagmus 10.3 CDKN2A TP53
30 endophthalmitis 10.3 CD34 SLC2A1
31 multiple mucosal neuroma 10.3 CD34 TP53
32 leiomyoma cutis 10.3 CDKN2A TP53
33 thyroid angiosarcoma 10.3 CD34 SOX10
34 anal squamous cell carcinoma 10.3 CDKN2A TP53
35 pleural empyema 10.3 NF2 S100B TP53
36 cowper gland carcinoma 10.2 CD34 TP53
37 colon leiomyosarcoma 10.2 CDKN2A NF1
38 hyperpituitarism 10.2 CD34 S100A1 SLC2A1
39 cervical adenomyoma 10.2 NF1 S100B TP53
40 breast myoepitheliosis 10.2 CDKN2A TP53
41 ritter's disease 10.2 CDKN2A TP53
42 epidural neoplasm 10.2 CDKN2A MDM2
43 rnase t2-deficient leukoencephalopathy 10.2 MDM2 TP53
44 fallopian tube squamous cell carcinoma 10.2 CD34 TP53
45 anaplastic oligodendroglioma 10.1 MDM2 NF2 S100B
46 acute cholinergic dysautonomia 10.1 MDM2 TP53
47 pancreatoblastoma 10.1 CDKN2A NF1 TP53
48 non-distal trisomy 10q 10.1 SLC2A1 TFG TP53
49 coccidiosis 10.1 CDKN2A TP53
50 skin lipoma 10.1 CD34 MDM2

Graphical network of the top 20 diseases related to Cellular Schwannoma:



Diseases related to Cellular Schwannoma

Symptoms & Phenotypes for Cellular Schwannoma

GenomeRNAi Phenotypes related to Cellular Schwannoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Cellular Schwannoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CD34 CDKN2A CHD4 DSP MDM2 NF1
2 behavior/neurological MP:0005386 10.35 TP53 CDKN2A MDM2 NF1 NF2 NGFR
3 embryo MP:0005380 10.28 CDKN2A CHD4 DSP MDM2 NF1 NF2
4 homeostasis/metabolism MP:0005376 10.27 CD34 CDKN2A MDM2 NF1 NF2 NGFR
5 growth/size/body region MP:0005378 10.25 NF1 NF2 NGFR SLC2A1 SOX10 SOX2
6 mortality/aging MP:0010768 10.21 NF2 NGFR SLC2A1 SOX10 SOX2 SUZ12
7 integument MP:0010771 10.2 DSP MDM2 NF1 NF2 NGFR S100B
8 immune system MP:0005387 10.18 CD34 CDKN2A CHD4 MDM2 NF1 NF2
9 digestive/alimentary MP:0005381 10.15 CDKN2A DSP MDM2 NF1 NGFR SOX10
10 endocrine/exocrine gland MP:0005379 10.13 CDKN2A CHD4 MDM2 NF1 NF2 SOX10
11 craniofacial MP:0005382 10.1 DSP MDM2 NF1 NF2 NGFR SOX2
12 nervous system MP:0003631 10.06 NF2 NGFR SLC2A1 SOX10 SOX2 SUZ12
13 neoplasm MP:0002006 10.02 CD34 CDKN2A MDM2 NF1 NF2 SOX10
14 muscle MP:0005369 10.01 CDKN2A DSP MDM2 NF1 NGFR S100A1
15 normal MP:0002873 9.86 S100B SOX10 SOX2 TP53 MDM2 NF1
16 pigmentation MP:0001186 9.7 CDKN2A MDM2 NF1 SOX10 SOX2 SUZ12
17 respiratory system MP:0005388 9.56 CDKN2A NF1 NF2 NGFR S100A1 SOX10
18 skeleton MP:0005390 9.23 CDKN2A MDM2 NF1 NF2 NGFR SOX2

Drugs & Therapeutics for Cellular Schwannoma

Drugs for Cellular Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
3 Gentamicins Phase 4
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
6
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
7
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
10 Alkylating Agents Phase 3,Phase 2,Phase 1
11 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
12 Isophosphamide mustard Phase 3,Phase 2
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Imatinib Mesylate Phase 2, Phase 3 123596
15
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
16
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
17
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
18
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Lenograstim Approved Phase 2 135968-09-1
21
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
22
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
23
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
24
nivolumab Approved Phase 2 946414-94-4
25
Gemcitabine Approved Phase 2 95058-81-4 60750
26
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
27
Pembrolizumab Approved Phase 2 1374853-91-4
28
Adenosine Approved, Investigational Phase 2 58-61-7 60961
29
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
30
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
31
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
34
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
35
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
36
Lactitol Investigational Phase 2 585-86-4 3871
37 Angiogenesis Inhibitors Phase 2,Phase 1
38 Angiogenesis Modulating Agents Phase 2,Phase 1
39 Antibodies Phase 2,Phase 1
40 Antibodies, Monoclonal Phase 2,Phase 1
41 Immunoglobulins Phase 2,Phase 1
42 Antifungal Agents Phase 2,Phase 1,Early Phase 1
43 Immunosuppressive Agents Phase 2,Phase 1,Early Phase 1
44 Endostatins Phase 2 71581480
45
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
46 Adjuvants, Immunologic Phase 2
47 Antineoplastic Agents, Phytogenic Phase 2
48 Etoposide phosphate Phase 2
49 Micronutrients Phase 2
50 Nicotinic Acids Phase 2

Interventional clinical trials:

(show top 50) (show all 68)

id Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Enrolling by invitation NCT02884154 Phase 4
4 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
7 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
8 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
9 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
13 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
14 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
15 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
16 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
18 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
19 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
20 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2 RAD001, everolimus
21 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
22 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
23 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
24 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
27 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
28 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
29 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
30 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
31 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
32 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
33 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2 Alisertib
34 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
35 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
36 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
37 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Suspended NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
38 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
39 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
40 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
41 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
42 Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting NCT03009201 Phase 1 Doxorubicin;Ribociclib
43 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Recruiting NCT00931931 Phase 1
44 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
45 Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Suspended NCT02700230 Phase 1
46 Concentration and Activity of Lapatinib in Vestibular Schwannomas Unknown status NCT00863122 Early Phase 1 lapatinib
47 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
48 NF2 Natural History Consortium Unknown status NCT00004483
49 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients Completed NCT01222728
50 Analysis of NF2 Mutations in Radiation-Related Neural Tumors Completed NCT00340496

Search NIH Clinical Center for Cellular Schwannoma

Genetic Tests for Cellular Schwannoma

Anatomical Context for Cellular Schwannoma

MalaCards organs/tissues related to Cellular Schwannoma:

39
Brain, Skin, Bone, Trigeminal Ganglion

Publications for Cellular Schwannoma

Articles related to Cellular Schwannoma:

(show top 50) (show all 62)
id Title Authors Year
1
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
2
Cellular schwannoma arising from the gastric wall misdiagnosed as a gastric stromal tumor: A case report. ( 24396458 )
2014
3
Infantile cellular schwannoma developing on the skin with atypical clinical features. ( 25232315 )
2014
4
Primary pleural hybrid cellular schwannoma/perineurioma: a case report. ( 24998375 )
2014
5
A recurrent cellular schwannoma. ( 25346907 )
2014
6
Cellular schwannoma of the retroperitoneum with cystic degeneration, mimicking an ovarian cyst, with CKAE1/AE3 and desmin expression. ( 25180931 )
2014
7
Spontaneous acute hemorrhage of intraspinal canal cellular schwannoma with paraplegia: A case report. ( 25488387 )
2014
8
An unusual location for cellular schwannoma. ( 24718004 )
2014
9
Atypical presentation of sinonasal cellular schwannoma: a nonsolitary mass with osseous, orbital, and intracranial invasion. ( 25083375 )
2014
10
Cellular schwannoma arising from sigmoid mesocolon presenting as torsion. ( 24349845 )
2013
11
Cellular schwannoma masquerading as malignant peripheral nerve sheath tumour: a diagnostic dilemma. ( 23709140 )
2013
12
A spinal epidural dumbbell cellular schwannoma in an infant. ( 22325076 )
2012
13
Low-back pain as the presenting sign in a patient with a giant, sacral cellular schwannoma: 10-year follow-up. ( 21214314 )
2011
14
Intrapulmonary cellular schwannoma. ( 20868846 )
2010
15
Trisomy 17 in congenital plexiform (multinodular) cellular schwannoma. ( 21156251 )
2010
16
Meningothelial-like whorls in a retroperitoneal cellular schwannoma: potential diagnostic pitfall. ( 20055955 )
2010
17
Non-healing ulcer on the great toe due to cellular schwannoma. ( 20055863 )
2009
18
Cellular schwannoma of the abducens nerve: case report and review of the literature. ( 19200646 )
2009
19
A huge cystic cellular schwannoma of the intercostal nerve presenting with dyspnea. ( 19324168 )
2009
20
Cellular schwannoma of the greater superficial petrosal nerve presenting with abducens nerve palsy and xerophthalmia: case report. ( 18981849 )
2008
21
A rare case of cellular schwannoma in the pharynx. ( 18306575 )
2007
22
Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report. ( 17695403 )
2007
23
Unusually large cellular schwannoma of the foot. ( 15778474 )
2005
24
Intrasellar and parasellar cellular schwannoma. ( 15185261 )
2004
25
Small juxtadrenal cellular schwannoma. ( 14634806 )
2004
26
Clonal chromosome abnormalities in a plexiform cellular schwannoma. ( 15041228 )
2004
27
Cellular schwannoma: report of a case diagnosed intraoperatively with the aid of cytologic imprints. ( 12889049 )
2003
28
Congenital and childhood plexiform (multinodular) cellular schwannoma: a troublesome mimic of malignant peripheral nerve sheath tumor. ( 14508393 )
2003
29
A rare case of cellular schwannoma involving the trigeminal ganglion. ( 14756445 )
2003
30
Cellular schwannoma: a rare spinal benign nerve-sheath tumor with a pseudosarcomatous appearance: case report. ( 14762614 )
2003
31
Retrobulbar cellular schwannoma. Two cases report and review of the literature. ( 12812319 )
2003
32
Cellular schwannoma: a rare presacral tumour. ( 11939658 )
2002
33
A case of cellular schwannoma of the skin presenting as a large ulcerated tumor on the ankle. ( 11837571 )
2002
34
Cellular schwannoma in the oral mucosa. ( 12126009 )
2002
35
Cellular schwannoma of the posterior fossa. ( 11971068 )
2002
36
Cellular schwannoma of the paranasal sinuses: initial report of a case. ( 11987747 )
2002
37
Cellular schwannoma of the mandible: a case report. ( 11429752 )
2001
38
Cellular schwannoma: a benign neoplasm sometimes overdiagnosed as sarcoma. ( 11465777 )
2001
39
Giant intrasacral cellular schwannoma treated with high sacral amputation. ( 11413442 )
2001
40
Solitary cellular schwannoma (neurilemmoma) showing malignant changes: evaluation through magnetic resonance imaging (M.R.I.), surgical intervention, and histopathology. ( 10209928 )
1999
41
Cellular schwannoma mimics a sarcoma: an example of a potential pitfall in aspiration cytodiagnosis. ( 10319235 )
1999
42
Solitary cellular schwannoma presenting with haemothorax. ( 10325881 )
1998
43
Retrovesical cellular schwannoma. ( 9117235 )
1997
44
Acoustic cellular schwannoma invading the petrous bone: case report. ( 8837812 )
1996
45
Cellular schwannoma: a clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. ( 8630970 )
1996
46
Cellular schwannoma of the mandible: a case report with ultrastructural and immunohistochemical observations. ( 8600243 )
1996
47
Cellular schwannoma of the bronchus. ( 8837342 )
1996
48
Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. ( 7850709 )
1995
49
Cellular schwannoma. ( 7978072 )
1994
50
Cellular schwannomas of the intracranial and intraspinal compartment: morphological and immunological characteristics compared with classical benign schwannomas. ( 8095064 )
1993

Variations for Cellular Schwannoma

Expression for Cellular Schwannoma

Search GEO for disease gene expression data for Cellular Schwannoma.

Pathways for Cellular Schwannoma

GO Terms for Cellular Schwannoma

Cellular components related to Cellular Schwannoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.77 CDKN2A CHD4 DSP MDM2 NF1 NF2
2 nucleolus GO:0005730 9.63 CDKN2A MDM2 NF1 NF2 SUZ12 TP53
3 cytoplasm GO:0005737 9.47 CD34 CDKN2A CHD4 DSP MDM2 NF1

Biological processes related to Cellular Schwannoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.8 CHD4 MDM2 S100A1 SOX2 SUZ12 TP53
2 negative regulation of protein kinase activity GO:0006469 9.67 CDKN2A NF1 NF2
3 cellular response to hypoxia GO:0071456 9.65 MDM2 S100B TP53
4 positive regulation of apoptotic process GO:0043065 9.55 CDKN2A NF1 NGFR S100B TP53
5 Ras protein signal transduction GO:0007265 9.54 CDKN2A NF1 TP53
6 positive regulation of protein export from nucleus GO:0046827 9.51 MDM2 TP53
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.46 NGFR SOX2
8 replicative senescence GO:0090399 9.43 CDKN2A TP53
9 positive regulation of gene expression GO:0010628 9.43 CD34 MDM2 TP53
10 amyloid fibril formation GO:1990000 9.1 MDM2
11 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
12 negative regulation of cell-matrix adhesion GO:0001953 8.8 CDKN2A NF1 NF2

Molecular functions related to Cellular Schwannoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.55 CD34 CDKN2A CHD4 SOX10 TP53
2 SUMO transferase activity GO:0019789 9.37 CDKN2A MDM2
3 S100 protein binding GO:0044548 9.32 S100A1 S100B
4 identical protein binding GO:0042802 9.17 MDM2 S100A1 S100B SLC2A1 SOX10 TFG
5 disordered domain specific binding GO:0097718 8.96 MDM2 TP53
6 protein binding GO:0005515 10.13 CDKN2A CHD4 DSP MDM2 NF1 NF2

Sources for Cellular Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....